CNS Pharmaceuticals Files 8-K Amendment
Ticker: CNSP · Form: 8-K/A · Filed: 2024-06-20T00:00:00.000Z
Sentiment: neutral
Topics: amendment, exhibits
TL;DR
CNS Pharma filed an amendment to its 8-K, mostly adding exhibits. No major news.
AI Summary
CNS Pharmaceuticals, Inc. filed an amendment (8-K/A) on June 20, 2024, to its current report originally filed on June 14, 2024. This amendment primarily concerns the addition of exhibits related to the company's business operations. The filing does not appear to disclose new financial results or material events beyond the exhibit additions.
Why It Matters
This amendment clarifies or adds exhibits to a previous filing, providing additional documentation for investors and regulators regarding CNS Pharmaceuticals' operations.
Risk Assessment
Risk Level: low — The filing is an amendment to add exhibits, not a disclosure of new material events or financial performance, thus posing low immediate risk.
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- June 14, 2024 (date) — Date of earliest event reported
- June 20, 2024 (date) — Filing date of amendment
- Nevada (jurisdiction) — State of incorporation
- Houston, Texas (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K/A filing?
The primary purpose of this 8-K/A filing is to amend a previously filed current report by adding exhibits.
When was the original report filed, and when was the amendment filed?
The original report was filed on June 14, 2024, and the amendment (8-K/A) was filed on June 20, 2024.
What is the state of incorporation for CNS Pharmaceuticals, Inc.?
CNS Pharmaceuticals, Inc. is incorporated in Nevada.
Where are the principal executive offices of CNS Pharmaceuticals, Inc. located?
The principal executive offices are located in Houston, Texas.
Does this amendment disclose any new financial results or material events?
Based on the provided text, this amendment primarily concerns the addition of exhibits and does not appear to disclose new financial results or material events.
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 8.7 · Accepted 2024-06-20 17:00:11
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Marke
Filing Documents
- cns_8ka1.htm (8-K/A) — 30KB
- cns_ex0501.htm (EX-5.1) — 16KB
- image_001.jpg (GRAPHIC) — 6KB
- 0001683168-24-004367.txt ( ) — 233KB
- cnsp-20240614.xsd (EX-101.SCH) — 3KB
- cnsp-20240614_lab.xml (EX-101.LAB) — 33KB
- cnsp-20240614_pre.xml (EX-101.PRE) — 22KB
- cns_8ka1_htm.xml (XML) — 4KB
01
Item 9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit Description 4.1 Form of Pre-Funded Warrant (1) 4.2 Form of Common Warrant (1) 5.1 ArentFox Schiff LLP Legal Opinion * 10.1 Form of Securities Purchase Agreement (1) 10.2 Financial Advisory Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners (1) 99.1 Press release dated June 14, 2024 (1) 104 Cover page Interactive Data File (embedded within the Inline XBRL document)* Notes: * Filed herewith. (1) Previously filed as an exhibit to our Current Report on Form 8-K filed with the SEC on June 14, 2024 . 3 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CNS Pharmaceuticals, Inc. By: /s/ Chris Downs Chris Downs Chief Financial Officer Dated: June 20, 2024 4